RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue
Authors:
- Kobe ReyndersKRKobe Reynders
- Els WautersEWEls Wauters
- Matthieu MoisseMMMatthieu Moisse
- Herbert DecaluwéHDHerbert Decaluwé
- Paul De LeynPLPaul De Leyn
- Stéphanie PeetersSPStéphanie Peeters
- Maarten LambrechtMLMaarten Lambrecht
- Kristiaan NackaertsKNKristiaan Nackaerts
- Christophe DoomsCDChristophe Dooms
- Wim JanssensWJWim Janssens
- Johan VansteenkisteJVJohan Vansteenkiste
- Diether LambrechtsDLDiether Lambrechts
Open Access
- 17 July 2018
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 131
Abstract
Gene expression of specific therapeutic targets in non-malignant lung tissue might play an important role in optimizing targeted therapies. This study aims to identify different expression patterns of fifteen genes important for targeted therapy in non-small cell lung cancer (NSCLC). We prospectively collected tissue of NSCLC and non-malignant lung tissue from 25 primary resected patients. RNA-sequencing and 450 K methylation array profiling was applied to both NSCLC and non-malignant lung tissue and data were analyzed for 14 target genes. We analyzed differential expression and methylation as well as expression according to patient characteristics like smoking status, histology, age, chronic obstructive pulmonary disease, C-reactive protein (CRP) and gender. TCGA data served as a validation set. Nineteen men and 6 women were included. Important targets like PD-L2 (p = 0.035), VEGFR2 (p < 0.001) and VEGFR3 (p < 0.001) were downregulated (respective fold changes = 1.8, 3.1, 2.7, 3.5) in tumor compared to non-malignant lung tissue. The TCGA set confirmed these findings almost universally. PD-L1 (p < 0.001) became also significantly downregulated in the TCGA set. In NSCLC, MUC1 (p = 0.003) showed a higher expression in patients with a CRP < 5 mg/L compared to > 5 mg/L. In the TCGA data but not in our primary data, PD-L1 & 2 were both borderline more expressed in tumors of active smokers vs. tumors of ex-smokers (p = 0.044 and 0.052). Our results suggest a lower PD-L1 & 2 and VEGFR expression in NSCLC vs. non-malignant lung tissue. Specific patient characteristics did not seem to change the overall expression differences as they were in line with the overall results. This information may contribute to the optimization of targeted treatments.Keywords
This publication has 31 references indexed in Scilit:
- Targeting Angiogenesis in Squamous Non-Small Cell Lung CancerDrugs, 2014
- A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- The determination and interpretation of the therapeutic index in drug developmentNature Reviews Drug Discovery, 2012
- IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation dataBioinformatics, 2012
- Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell CarcinomaJournal of Thoracic Oncology, 2011
- Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysisBMC Bioinformatics, 2010
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid CancersClinical Cancer Research, 2010
- DNA Methylation and Cancer2010
- Perisurgical smoking cessation and reduction of postoperative complicationsAmerican Journal of Obstetrics and Gynecology, 2005
- Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2Cancer, 2005